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Abstract
Background: We recently characterized a progenitor of mesodermal lineage (MPCs) from the human bone marrow of adults
or umbilical cord blood. These cells are progenitors able to differentiate toward mesenchymal, endothelial and
cardiomyogenic lineages. Here we present an extensive molecular characterization of MPCs, from bone marrow samples,
including 39 genes involved in stem cell machinery, differentiation and cell cycle regulation.
Methodology/Principal Findings: MPCs are cytofluorimetrically characterized and quantitative RT-PCR was performed to
evaluate the gene expression profile, comparing it with MSCs and hESCs lines. Immunofluorescence and dot-blot analysis
confirm qRT-PCR data. MPCs exhibit an increased expression of OCT4, NANOG, SALL4, FBX15, SPP1 and to a lesser extent c-
MYC and KLF4, but lack LIN28 and SOX2. MPCs highly express SOX15.
Conclusions/Significance: MPCs express many pluripotency-associated genes and show a peculiar Oct-4 molecular circuit.
Understanding this unique molecular mechanism could lead to identifying MPCs as feasible, long telomeres, target cells for
reprogramming with no up-regulation of the p53 pathway. Furthermore MPCs are easily and inexpensively harvested from
human bone marrow.
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Introduction
Pluripotency has been the object of increasing interest and has
been extensively debated over the last few years. Adult stem cells
provide fascinating prospects for clinical applications emerging
from the recent advances in obtaining pluripotent cells. As clearly
summarized by Beltrani et al [1], at present, pluripotent cells may
be obtained by two main approaches: 1) inducing pluripotency in
somatic cells by manipulation or 2) by identification and isolation,
in adult tissues, of very rare cells exhibiting multilineage
differentiation. Different strategies for reprogramming somatic
cells along with different approaches in isolating and culturing rare
adult stem cells, i.e. marrow-isolated adult multilineage inducible
(MIAMI) [2], very small embryonic-like (VSEL) [3] and
multipotent adult progenitor (MAPC) [4] cells, lead to controver-
sial interpretation of the biological aspects of pluripotency.
However, increased interest and a large number of studies on
induced pluripotent stem cells (iPSCs) [5,6] help to clarify some
relevant aspects of stem cell machinery. The first evidence that
forced the expression that four transcription factors (Oct-4, Sox2,
Klf-4 and c-myc) can induce pluripotency in mouse fibroblasts [7]
started the investigation of relevant aspects about the molecular
mechanisms that govern pluripotency. Subsequently, Yu et al. [8]
obtained iPSCs in humans by transfecting with OCT4, SOX2,
NANOG and LIN28. Many attempts have been carried out to
reveal which factors are really required to obtain iPSCs and if
transfection is a unique method. In order to reduce the risks of
genetic modifications, representing the main obstacle for the safe
clinical use of these cells, several groups have tried to obtain
pluripotency by transient transfection [9], transposones [10],
adenoviral [11], episomal vectors [12] or recombinant proteins
[13]. Nonetheless, even though these new approaches lead to the
preservation of the genome integrity of reprogrammed cells,
current techniques to induce pluripotency are not at present
pursuable due to their low efficiency and only partial reprogram-
ming. Recent studies suggest that the use of adult progenitor cells,
i.e. neural stem cells in mice [14] or hematopoietic stem cells [15],
as starting cells give rise to iPSCs more rapidly and with a higher
efficiency, probably being epigenetically responsive to nuclear
resetting. Furthermore, the use of progenitors constitutively
expressing one or more reprogramming factors should allow the
obtaining of iPSCs with a reduced number of transfection vectors.
Neural stem cells that constitutively express Sox2 have been
reprogrammed by the single factor OCT4 in mice [16] and
humans [17]. From the assumption that progenitors are more
reliable, due to the less stringent epigenetic restriction, Eminli et al,
evaluating as starting cells hematopoietic stem cells versus mature
T and B cells, provide evidence that the differentiation stage could
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model of reprogramming [18].
Recently we described a simple and inexpensive culture method
to isolate highly selected mesodermal progenitor cells (MPCs) from
human bone marrow and umbilical cord blood [19], which may
be useful as starting cells for reprogramming. These cells have
been previously described in mesenchymal stromal cell (MSC)
cultures, performed in autologous serum [20]. MPCs exhibited
unusual morphology and a unique phenotype and remain
attached to the culture flasks after trypsin digestion. Attempts to
expand MPCs failed and revealed their ‘‘resting’’ state, which was
also confirmed by Ki-67 negativity and evaluated by incorporation
of 5-bromodeoxyuridine. Interestingly, when cultured in foetal calf
serum (FBS) or human cord blood serum, MPCs were able to
differentiate into highly proliferative and clonogenic MSCs. In
parallel, MPCs were able to efficiently differentiate towards
endothelial lineage, producing mature endothelial cells able to
give rise to tube-like structures in 3D-cultures [19]. Moreover,
some evidence suggests a cardiomyogenic differentiation capacity
of MPCs, revealing the capacity to generate quadri- or trigonal
cells positive for a-actinin and troponin I (data not shown). Taken
together these results define MPCs as multipotent progenitors of
mesodermal lineage, easily harvested from the bone marrow of
adults. From the first characterization, MPCs revealed expression
of the pluripotency-associated markers SSEA-4 and nuclear factors
Oct-4 and Nanog. Clarifying mechanism of Oct-4 expression by
these adult cells, and its regulation circuit, could lead to a better
understanding of MPCs’ biology and their clinical role. Further-
more, extended studies could reveal new interesting involvements
for the transcription factor Oct-4. Here we present an extensive
molecular characterization of highly purified MPCs, including 39




The study protocol was approved by the ethical committees of
Azienda Ospedaliera Universitaria Pisana. The fundamental
principles of ethics in research on human participants were
maintained throughout the study period. The research procedures
were disclosed to all participants and written informed consent was
obtained for sample collection.
Donors and cell cultures from bone marrow
Bone marrow mononuclear cells were collected, after written
consent, from twelve patients (9M/3F, median age: 61y)
undergoing cardiac surgery. Cells were cultured using a standard
protocol (Dulbecco’s modified minimal essential medium, DMEM
supplemented with 10% of FBS) to obtain MSCs, in parallel
800,000 cells/cm
2 were cultured in DMEM supplemented with
10% of pooled human AB type serum (PhABS, Lonza; Walkers-
ville MD-USA) in hydrophobic plastic flasks as previously reported
[19]. After 12-15 days of culture cells were detached by TrypLE
SelectH (Invitrogen, San Diego CA-USA) digestion and gentle
scraping. To assay purity of cultures, aliquots of cells were
processed for cytofluorimetric analysis using antibodies for SSEA-4
AlexaFluor-488H conjugated (Biolegend, San Diego CA-USA),
MSCA-1 PE-conjugated (Miltenyi, Bergisch Gladbach, GER),
CD105 PE-conjugated (Biolegend) and CD90 PE/Cy5-conjugated
(Biolegend). Data were acquired and analyzed by FACScanH
equipped with CellQuestH Software (BectonDickinson, San Jose,
CA-USA). MPC cultures were assessed and subsequently pro-
cessed for molecular characterization when rates of MSCA-
1
+CD90
bright (MSC phenotype) were lower than 2%. Similarly,




(MPC phenotype) elements were ,2%.
Quantitative RT-PCR
Total RNA was extracted using an RNeasy Mini Kit (Qiagen
GmbH, Hilden, Germany) as indicated by the manufacturer’s
protocol. On-column DNase I digestion was performed. 100 ng of
each RNA sample was retrotranscribed with QuantiTect Whole
Transcriptome Kit (Qiagen) and a 50-fold dilution of cDNAs was
analyzed by quantitative Real Time PCR (qRT-PCR) using an
iCycler-iQ5 Optical System (Bio-Rad Laboratories, Hercules, CA-
USA) utilizing iQ SYBR Green SuperMix (Bio-Rad). All samples
were run in duplicate. Primers (see Supplemental Table S1) were
designed from coding sequences published in Gene Bank with the
help of either Beacon Designer Software (Premier Biosoft
International,Palo Alto, CA-USA) or from a Human Pluripotent
Stem Cell Assessment Kit (R&D Systems, Minneapolis MN-USA)
and clustered in four groups: ‘‘Pluripotency-associated genes’’
(including OCT4, its cofactors and target genes), ‘‘Commitment-
associated genes’’, ‘‘Sox family genes’’ and ‘‘other genes’’ of
interest. Relative quantitative analysis was performed following
2-
DDCt Livak method [21]. Normalization was performed with the
housekeeping genes GAPDH and HPRT. Statistical analysis was
performed by applying the two tailed t test. Subsequently, qRT-
PCR of pluripotency-associated genes, SOX2 and SOX15 were
also performed on mRNA extracted from three human embryonic
stem cell (hESCs) lines; BG01V, I6 and H9. Inter-run calibration
was performed by the internal calibrator method as previously
described [22]. Telomere length assay was performed using the
TeloTAGGG assay kit (Roche, Madison, WI-USA) according to
the manufacturer’s instructions, and median telomere restriction
fragment (TRF) length was evaluated by Leica QWin image
analysis software (Leica, Wetzlar, Germany).
Tri-colors Immunofluorescence
FBS and PhABS cultures were performed, in parallel, on
PermanoxH double-chamber slides (Nunc, Rochester, NY-USA) as
described above. After 8–10 days slides were fixed for 15 min in
periodate-lysine-paraformaldheyde and made permeable by Tri-
ton-X100 0.05% for 30 min. Immunofluorescence was performed
using anti-Oct-4 (Santa Cruz, CA-USA), anti-Nanog (BectonDick-
inson), anti-Sox15 and anti-Nestin (ABCam, Cambridge, UK) as
primary antibodies and revealed by Goat anti-mouse SFX kit
(Invitrogen) according to the manufacturer’s instructions using
AlexaFluorH-488 anti-mouse IgG. Subsequently slides were
stained by Phalloidin AlexaFluorH-555 conjugated (Invitrogen)
for 30 min to reveal actin organization, and mounted in ProlongH
Gold antifade reagent with 49,6-diamidino-2-phenylindole (DAPI)
(Invitrogen) to allow nucleus localization. Pictures were taken and
combined using a standard fluorescence DMR Leica microscope
(Leica) equipped with Leica CW4000 image software (Leica).
Dot-Blot Analysis
For three of the most abundant samples an aliquot of 300,000–
600,000 cells from FBS or PhABS cultures was washed and pellets
were processed for protein extraction of nuclei contents using the
kit from Active-Motif (Carlsbad, CA-USA). Extracted proteins
(10 ml) were spotted, in quintuplicate, on nitrocellulose membranes
(Bio-Rad, Hercules CA-USA). Membranes were processed for
staining with anti-Oct-4 (Santa Cruz) and anti-Sox15 (ABCam)
and revealed by HRP-conjugated secondary antibody (ABCam)
and subsequent incubation with ECL reagent (ABCam). Images
were acquired by ChemiDoc digital imaging system (Bio-Rad) and
MPCs and Adult Oct-4 Circuit
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data is presented as mean 6 standard error (SE).
Results
Ten samples produced highly monomorphic cultures (Figure
1A) showing typical spindle-shaped cells (MSCs) in FBS cultures,
or rounded and highly rifrangent cells (MPCs) in PhABS cultures.
Flow cytometry confirmed purity and phenotype of the cells












neg. Two samples were re-
jected due to a higher contaminating MSC rate in MPC cultures.
We also assessed telomere length utilizing the Southern method,
determining median terminal restriction fragment (TRF) length.
TRF length was shorter (5.88 kb) in MSCs than in MPCs (9.00 kb)
(Figure 1C). This latter value is near to the values reported for
passaged human embryonic cell lines [23] or human iPSCs [24].
Total mRNA was extracted, reverse transcripted and evaluated
by quantitative RT-PCR for expression of genes involved in the
characterization of stem cells: undifferentiated ESCs (OCT4,
NANOG, SALL4, DPPA5, REX-1, STAT3, FBX15, FOXD3,
SPP1, FGF4) (Figure 2A), ectodermal committed SCs (NESTIN,
OTX2), endodermal committed SCs (a-Fetoprotein AFP, GATA-
4, PDX-1, FOXA2), mesodermal committed SCs (Brachyury,
GATA6, RUNX2, PPARc) and germ cells (Stella) were evaluated
(Figure 2B). Sox family genes were also evaluated (SOX1, SOX2,
SOX3, SOX9, SOX11, SOX12, SOX15, SOX17, SOX18 and
SOX21) (Figure 2C) alongside other reprogramming factors that
included c-MYC, KLF4 and LIN28; p53 circuit was evaluated by
qRT-PCR for TP53, TP63 and TP21. To complete the analysis
qRT-PCR was also performed to study two other genes regulated
by Oct-4/Sox15 complex i.e. CTGF and EBAF (Figure 2D).
Quantitative RT-PCR analysis revealed high levels of genuine
OCT-4 (isoform A) mRNA in MPCs only (p,0.01) alongside the
expression of NANOG (p,0.01) (Figure 2A). FOXD3, STAT3,
SALL4 usually involved in OCT4 and NANOG activation in
pluripotent stem cells were also detected in MPCs. Oct-4 target
genes such as REX-1 and DPPA5 or FGF4 were not detected. In
contrast, consistent expression of FBX15 (p,0.01) and SPP1
Figure 1. Mesodermal Progenitor Cells (MPCs) differ from MSCs and show unusual immature gene expression pattern. A)
Mesodermal progenitor cells (MPCs) are easily distinguishable in culture from typical spindle-shaped MSCs by their characteristic fried egg-like shape
(bars=50 mm): rounded cells with a thick core region that is highly rifrangent. B) Cytofluorimetric analysis allows evaluation of the purity of selective
cultures. MPCs show a high SSC signal, stain brightly with anti-SSEA-4 antibody and lack the mesenchymal markers CD90 and MSCA-1. MPCs share
expression of CD105 with MSCs, but at a lower signal. C) Telomere length assay, values of medians TRF are reported, at the end of the lanes, for two
paired samples (#1, #2, MW: molecular weight).
doi:10.1371/journal.pone.0009861.g001
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associated genes were detected except NESTIN (p,0.05) and
PPARc (p,0.001), which were highly expressed by MPCs
(Figure 2B). Despite these cells expressing the above mentioned
genes, typically associated with Oct-4 circuit activation, SOX2
expression was not revealed in MPCs, while high levels of SOX15
(p,0.01) were detected (Figure 2C), suggesting the possibility of
direct interaction of Oct-4 and Sox15 (in place of Sox2). Expression
of MPC exclusively associated markers (Nanog, Oct-4, Sox15 and
Nestin) was confirmed by immunofluorescence (Figure 3). Actin
organization allows the identification of MPCs. As previously
reported [18,19], MPCs showed a dotted pattern of F-actin, often
organized in rosettes (arrows). In contrast, long fibres of
polymerized actin characterized MSCs. Nuclear localization of
Oct-4 and Sox15 was further confirmed by dot-blot analysis of
nuclear proteins extract (Supplemental Figure S1). In the ‘‘other
genes’’ panel we reported expression of KLF4, c-MYC but not
LIN28. TP53 and TP21 were expressed, with no significant
differences, by the two populations, but otherwise TP63 levels
were lower in MPCs (p,0.05) (Figure 2D).
To compare the Oct-4 ‘‘adult’’ circuit in MPCs to the embryonic
one, we performed qRT-PCR of pluripotency-associated genes,
SOX2 and SOX15 on mRNA from three human embryonic cell
lines (BG01V, I6 and H9). As might be expected, median relative
normalized expression of OCT4 and NANOG in the embryonic
lines turned out to be 2.5 logs higher (p,0.05) than in MPCs
(Figure 4). As expected, hESC lines showed consistent expression
of SOX2 and SOX15 was also expressed with no significant
difference compared to MPCs. Some Oct-4 target genes/co-factors
not expressed by MPCs, such as REX-1, DPPA5 and FGF4, were
in contrast expressed in hESCs while SALL4 and FOXD3 showed
increased expression in embryonic cells (p,0.01, data not shown).
Despite these quantitative differences in OCT4 and SOX2
expression, some Oct-4 target genes, such as KLF4, FBX15 and
SPP1, were expressed with no significant differences between
MPCs and hESCs (data not shown).
Discussion
Our results define MPC as a human progenitor easily
obtainable from adult bone marrow that constitutively express
Oct-4, which is considered to be the core factor associated with
pluripotency. From the first characterization and isolation in adult
bone marrow, MPCs reveal their early progenitor nature, together
with their ability to produce several generations of MSCs and
different multilineage commitments [19]. We initially reported
expression of Oct-4 and Nanog by immunofluorescence and
qualitative RT-PCR, so that we hypothesized that MPCs could
show a molecular program regulated by Oct-4. The results
presented in this paper confirm the genuine expression of
functional Oct-4, avoiding the misinterpretation due to pseudo-
genes and non-functional isoforms. Importantly, only the long
isoform, OCT4A, has been reported to be responsible for the stem
properties [25] and can sustain the stem cell self-renewal [26].
Figure 2. Quantitative RT-PCR analysis of 10 samples from MPCs (red squares) or MSCs (black dots). A) Pluripotency-associated
genes, B) Commitment-associated genes, C) Sox family genes and D) other genes of interest. Data are normalized and expressed as media +/2 SEM
(* p,0.05; ** p,0.01, *** p,0.001).
doi:10.1371/journal.pone.0009861.g002
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unusual activation of the Oct-4 regulatory circuit probably related to
the lack of Sox2. The deregulation of ‘‘embryonic’’ Oct-4/Sox2 target
genes (FGF4, FBX15, and OCT4, SOX2 themselves) suggests the
activity of the complex Oct-4/Sox15 (in place of Oct-4/Sox2 which is
the core transcription complex in the ‘‘embryonic’’ circuit or
‘‘canonical’’ circuit). Detection of SOX15 in MPCs in a quantity
similar to hESC could explain the expression of FBX15 that is
reported as being also an Oct-4/Sox15 target gene in murine ESCs
[27]. On the contrary, CTGF, OTX2 and EBAF were not up-
regulated in MPCs, in contrast to the reported data on hESCs,
suggesting a defective activity of complex Oct-4/Sox15 or the
activation of a further control mechanism for gene transcription.
This possibility is suggested by consistent expression of SPP1 in
MPCs. In fact, Botquin et al. reported that SPP1 reveals a
palindrome Oct factor recognition element (PORE) in the enhancer
region, which is able to bind homodimers of POU proteins. The
authors provided consistent evidence that the PORE region of
SPP1 is a target for the homodimer of Oct-4 and that this binding
transactivates more strongly than the canonical octamer motif [28].
As reported, Spp1 was secreted by pre-implantation embryos and
hESCs lines express SPP1 at different levels. Interestingly, different
levels of SPP1 expression inversely correlates with the expression
levels of Sox2, which inhibit the Oct-4 homodimer activity.
It is possible that adult Oct-4 activity, detected in MPCs, involve
interaction with Sox15 (binding HMG domains) alongside self-
dimerization (binding POREs), resulting in a characteristic
transcriptional signature. In ‘‘adult’’ Oct-4 circuit the SOX2 gene
is fully silenced while the other pluripotency-associated co-factors
such as NANOG, KLF4, cMYC and SALL4 are expressed with
insignificant differences in MPCs and hESCs. The lack of SOX2
seems to represent the principal difference between pluripotent
and adult Oct-4 circuits, it could play a very important role in
control of the MPC’s fate and may be an important difference in
their ontogenesis.
Taken together, these results suggest that the complex Oct-4/
Sox2 is the core factor which differentiates the pluripotent
(embryonic) Oct-4 molecular program from the adult one detected
in Oct-4 expressing MPCs. Further confirmation is provided by
recent papers reporting that a fully pluripotent state can be
induced in Sox2 expressing neural stem cells in mice [16] and in
humans [17] by single factor Oct-4 transfection. This suggests that
the sole induction of Sox2 in MPCs could lead to trigger a
reprogramming process in easily obtainable bone marrow cells.
The constitutive expression of co-factors like Nanog, Klf-4 and c-myc
in MPCs further sustains the single factor (1F) reprogramming
hypothesis, as reported for foetal neural induced stem cells. Klf-4
and c-myc endogenously expressed in the starting cells, make
forcing their expression dispensable [17].
Moreover, efficiency in reprogramming MPCs could be expected
to be increased when compared to somatic cells due to their early
undifferentiated nature. In fact, it has been reported that adult
progenitors are more reliable for reprogramming than terminally
differentiated cells [14,15] due to the less stringent epigenetic
restriction that favours nuclear reprogramming. Nevertheless, the
epigenetic restriction is only one of the conditions that limit the
kinetics and efficiency of pluripontency induction. In fact, forcing
expression of Oct-4, Sox2, Klf-4 and c-myc triggers senescence and up-
regulation of p53/p21 [29], which negatively influence the
percentage of fully reprogrammed iPSCs. In MPCs, high expression
of Oct-4 and Nanog and other co-factors is not associated with a
significantly increased expression of p53 and p21, compared to
proliferating hESC or MSCs, alongside long telomeres.
The true significance for the adult Oct-4 circuit in ‘‘in vivo’’
precursor of MPCs is still unclear: it could be required for the
maintenance of immature features together with the need to
preserve bone marrow homeostasis, but it cannot be ruled out that
its deregulation could be at the basis for transforming MPCs into
tumour-initiating cells. Recently, it has been reported that the
expression of Oct-4, and co-factors, plays a fundamental role in the
induction of cancer stem cells, as tumour-initiating cells in Ewing’s
sarcoma [30].
MPCs are very attractive and could open new prospective
clinical applications for reprogrammed cells. Further studies are
needed to attempt reprogramming not only by SOX2 transfection
but also by evaluating the opportunities to induce expression of
Sox2 by signalling modulation, i.e Wnts [31], Activin/Nodal [32]
and/or Hedgehog [33].
Over the last few years, in vitro induction of pluripotency has
seemed to offer greater potential when compared to the
problematic isolation of rare adult stem cells in the potential use
of pluripotent cells in therapy. However, the generation of an
efficient virus-free strategy for reprogramming represents a crucial
Figure 3. MPCs express Nanog, Oct-4 and Sox15 but no Sox2 in
the nucleus. Indirect immunofluorescent stain confirms the expression
of Nanog, Oct-4 and Sox15 (green) in MPCs’ nuclei (blue) but not in
MSCs easily distinguishable from mesodermal progenitors by different
spatial organization of F-actin (red). MPCs also differ from MSCs due to
their unexpected high expression of well-organized Nestin filaments
(green) as shown by the lower panels. Green fluorescent isotype
controls reveal no specific signal (data not shown).
doi:10.1371/journal.pone.0009861.g003
MPCs and Adult Oct-4 Circuit
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could be an alternative, as they are not so rare in adult bone
marrow and the isolating procedure is easy and inexpensive [18].
MPCs reveal a peculiar Oct-4 circuit activation that, hopefully,
could be modulated toward pluripotency without genetic manip-
ulation, i.e. by signal inhibition as reported for NSCs that are
presently unavailable in human adults.
Supporting Information
Figure S1 Dot-Blot analysis of nuclear extract detect presence of
Oct-4 and Sox15 transcription factors in MPCs. In three MPC
samples with higher cell count it has been possible to perform dot-
blot analysis to confirm the presence of Oct-4 and Sox15 in the
nuclear proteins extracts. Densitometric evaluation of spots were
performed excluding the higher and the lower signal of the five
repeats.
Found at: doi:10.1371/journal.pone.0009861.s001 (0.54 MB TIF)
Table S1 Primer pairs designed for gene expression analysis.
Found at: doi:10.1371/journal.pone.0009861.s002 (0.42 MB
RTF)
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